Want to see PMI full AI Analyst Report?
PMI Stock Chart & Stats
$1.82
--
Market closed
$1.82
--
Day’s Range― - ―
52-Week Range$0.11 - $13.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.38M
Market Cap
$15.90M
Enterprise Value$300.41M
Total Cash (Recent Filing)$121.00K
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta-2.53
Next Earnings
Sep 21, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding92,349,846
10 Day Avg. Volume2,124,305
30 Day Avg. Volume2,378,935
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap18.89
Enterprise Value/Revenue54.85
Enterprise Value/Gross Profit360.64
Enterprise Value/Ebitda-12.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sole FDA‑approved Total Artificial HeartPicard’s SynCardia franchise holds a durable competitive advantage as the only FDA‑ and Health Canada‑approved total artificial heart, with >2,100 implants across 27 countries. That exclusive regulatory position creates high barriers to entry, strong clinical adoption momentum, and long lead tubing for competitors, supporting recurring procedure and device-related revenue over the medium term.
Revenue Growth & Margin ImprovementRecent top‑line acceleration and clear gross margin recovery (Q1 +85% and 24% gross margin; TTM revenue +10.7%, gross margin ~15%) indicate the business is moving from negative unit economics toward operating leverage. Durable margin expansion from higher device utilization and Freedom Driver rentals can sustainably improve cash generation as scale increases, assuming continued commercial execution.
Reduced Secured Debt And Fresh EquityMaterial reduction in senior secured indebtedness alongside a May 2026 equity raise (~$5M) and warrant restructuring meaningfully eased near‑term creditor pressure. Improved leverage enhances financial flexibility, lowers interest burden, and extends runway—structural improvements that reduce immediate refinancing risk and support investment in commercial scale and R&D over the next several quarters.
Bears Say
High Cash BurnPersistent and large negative operating and free cash flows indicate the company continues to consume significant capital to fund operations. This structural cash burn necessitates repeated external financing, increasing dilution and financing costs, and constraining the company’s ability to self‑fund commercialization and R&D until operations move meaningfully toward break‑even.
Negative Equity And Listing NoncomplianceA stockholders’ deficit and formal NYSE American noncompliance notice are structural governance and financing headwinds. Negative equity limits borrowing capacity and can precipitate restrictive remediation plans or delisting if unresolved, raising the probability of costly recapitalizations or constrained strategic options over the medium term.
Very Large Operating LossesExtremely wide negative operating and net margins reflect that current revenue levels are far from covering fixed and operating costs. This structural profitability gap implies the business model must scale substantially or materially reduce costs to reach sustainable profitability; until then, reliance on external capital and execution risk remain elevated.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $0.11 and its highest was $13.68 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Picard Medical, Inc.’s market cap is $15.90M.
When is Picard Medical, Inc.’s upcoming earnings report date?
Picard Medical, Inc.’s upcoming earnings report date is Sep 21, 2026 which is in 80 days.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on May 21, 2026. The company reported -$0.1 earnings per share for the quarter, the consensus estimate of -$0.1 by $0.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 92,349,846 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$0.1 in its last earnings report, expectations of -$0.1. Following the earnings report the stock price went down -8.442%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
PMI Company Deck
PMI Earnings Call
Q4 2026
0:00 / 0:00
PMI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
0.11% Mutual Funds
0.05% Other Institutional Investors
99.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---